Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion (XYN-Bev MPE)
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.
The goal of this clinical trial is to determine whether the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage is effective in treating malignant pleural effusion. It will also evaluate the safety of this combination therapy. The main questions it aims to answer include:
Does the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage improve the objective response rate (ORR) of pleural effusion in patients with malignant pleural effusion? Does this combination therapy affect the duration of response (DoR), progression-free survival (PFS), overall survival (OS), degree of dyspnea, quality of life, and Traditional Chinese Medicine (TCM) pattern/syndrome evaluation in patients with malignant pleural effusion?
Participants will:
Receive intrapleural injection of bevacizumab via chest tube drainage, and take either Xuanyin Ning Formula or placebo granules daily for 8 weeks.
Undergo ultrasound assessment of pleural effusion at 2, 4, 8, and 12 weeks after the first intrapleural injection during closed chest drainage, followed by ultrasound assessments every 3 months (±7 days) until pleural effusion progression.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Ming Zhang
- Telefonní číslo: 18017320233
- E-mail: gason2000@126.com
Studijní místa
-
-
Hebei
-
Wuhan, Hebei, Čína, 430022
- Wuhan First Hospital
-
Kontakt:
- Zuowei Hu
- Telefonní číslo: 13871029959
- E-mail: 827823053@qq.com
-
-
Henan
-
Xinxiang, Henan, Čína, 453100
- The First Affiliated Hospital of Xinxiang Medical University
-
Kontakt:
- Xiaohong Kang
- Telefonní číslo: 19838276658
- E-mail: 394161891@qq.com
-
-
Shandong
-
Weifang, Shandong, Čína, 261041
- Weifang Traditional Chinese Medicine Hospital 或 Weifang Traditional Chinese Hospital
-
Kontakt:
- Chaoguang Yan
- Telefonní číslo: 19953614610
- E-mail: 19953614610@126.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200030
- Shanghai Chest Hospital
-
Kontakt:
- Ming Zhang
- Telefonní číslo: 18017320233
- E-mail: gason2000@126.com
-
Shanghai, Shanghai Municipality, Čína, 200437
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
-
Kontakt:
- Yabin Gong
- Telefonní číslo: 18918923873
- E-mail: gongyabin@hotmail.com
-
Shanghai, Shanghai Municipality, Čína, 200032
- Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
-
Kontakt:
- Zhongqi Wang
- Telefonní číslo: 18917763093
- E-mail: aledx@sina.com
-
Shanghai, Shanghai Municipality, Čína, 202157
- Shanghai Tenth People's Hospital Chongming Branch
-
Kontakt:
- Yeyun Lu
- Telefonní číslo: 18916582319
- E-mail: 307997868@qq.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Patients with advanced non-squamous non-small cell lung cancer who have failed at least first-line systemic therapy;
- Presence of unilateral pleural effusion confirmed as malignant by pathology or cytology, with at least moderate volume requiring drainage (moderate pleural effusion defined as: supine ultrasound examination showing pleural effusion ≥3 cm, or sitting ultrasound examination showing pleural effusion ≥4 cm,accompanied by clinical symptoms such as chest tightness and dyspnea);
- Age 18-75 years;
- ECOG performance status 0-2;
- Traditional Chinese Medicine (TCM) syndrome differentiation classified as Xuanyin (suspension fluid) with fluid retention in the chest and hypochondrium;
- Expected survival of at least 3 months;
- Voluntarily signed informed consent before treatment;
- No contraindications to chest tube placement for drainage;
Adequate major organ function, including:
Complete blood count:
White blood cell count ≥ 4.0×10⁹/L Absolute neutrophil count ≥ 1.5×10⁹/L Platelet count ≥ 100×10⁹/L Hemoglobin ≥ 90 g/L
Blood biochemistry:
Total bilirubin ≤ 1.5×ULN ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Coagulation function:
International normalized ratio (INR) ≤ 1.5×ULN Activated partial thromboplastin time (APTT) ≤ 1.5×ULN
- Blood glucose: within normal range, or diabetic patients under treatment with stable blood glucose control;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug administration, and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study period and for at least 3 months after the last dose. -Male subjects with a partner of childbearing potential must use effective contraception during the study period and for 3 months after the last dose;
- Good subject compliance, able to follow up for efficacy and adverse events/reactions as required by the protocol.
Exclusion Criteria:
- The location of pleural effusion is unsuitable for drainage, or the patient would not benefit from intrapleural drug administration (e.g., severe loculation/septation);
- Other contraindications to indwelling chest tube placement;
- Pleural effusion with active infection;
- Prior history of ipsilateral chest tube drainage and intrapleural anti-tumor drug therapy or pleurodesis;
- Prior history of empyema or chylothorax;
- Participation in another clinical trial within 4 weeks before signing informed consent;
- Known allergy to any component of the study drugs;
- Severe bleeding tendency or active bleeding;
- Uncontrolled severe hypertension;
- Recent (within 3 months) thromboembolic events, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, etc.;
- Prior severe adverse reactions to intravenous bevacizumab, such as severe proteinuria, gastrointestinal perforation, hypertensive crisis, etc.;
- Severe cardiac, hepatic, or renal insufficiency;
- Pregnant or breastfeeding women;
- Subjects with other active infectious diseases in the acute phase;
- Any other factors that, in the investigator's judgment, may lead to premature termination of the study, such as other serious diseases (including psychiatric disorders) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the subject's safety or compliance.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: experimentální skupina
|
After chest tube drainage, bevacizumab 300 mg per dose, dissolved in 50 ml of normal saline, is injected intrapleurally.
The injection may be repeated after 2 weeks depending on the control of pleural effusion.
Xuanyin Ning is taken as 2 sachets per day, one sachet dissolved in water and taken orally in the morning and one in the evening.
Each treatment cycle is 4 weeks, and at least 2 cycles are required.
|
|
Komparátor placeba: kontrolní skupina
|
After chest tube drainage, bevacizumab 300 mg per dose, dissolved in 50 ml of normal saline, is injected intrapleurally.
The injection may be repeated after 2 weeks depending on the control of pleural effusion.
Placebo granules are taken as 2 sachets per day, one sachet dissolved in water and taken orally in the morning and one in the evening.
Each treatment cycle is 4 weeks, and at least 2 cycles are required.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Objective Response Rate of pleural effusion (ORR)
Časové okno: Before treatment and at 4 weeks, 8 weeks, and 12 weeks after treatment
|
Before treatment and at 4 weeks, 8 weeks, and 12 weeks after treatment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Duration of Response (DoR)
Časové okno: At 2, 4, 8, and 12 weeks after treatment
|
At 2, 4, 8, and 12 weeks after treatment
|
|
|
Progression-Free Survival (PFS)
Časové okno: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
|
|
Overall Survival (OS)
Časové okno: From date of treatment until the date of death from any cause, assessed up to 100 months
|
From date of treatment until the date of death from any cause, assessed up to 100 months
|
|
|
Degree of dyspnea
Časové okno: At 2, 4, 8, and 12 weeks after treatment
|
At 2, 4, 8, and 12 weeks after treatment
|
|
|
ECOG score
Časové okno: At 2, 4, 8, and 12 weeks after treatment
|
The ECOG score is a widely used clinical tool for quantifying a cancer patient's general well-being and functional capacity in daily life.
It is primarily employed in oncology trials, treatment planning, and prognosis assessment.
The scale ranges from 0 to 5, with higher numbers indicating greater disability
|
At 2, 4, 8, and 12 weeks after treatment
|
|
Traditional Chinese Medicine (TCM) syndrome evaluation
Časové okno: At 2, 4, 8, and 12 weeks after treatment
|
Quantification: The scale standardizes the evaluation of clinical symptoms, signs, and tongue/pulse findings, which are traditionally assessed through the four examinations (inspection, hearing/smelling, inquiry, and palpation). Objectivity: It aims to improve the objectivity and standardization of TCM diagnosis and treatment evaluation. Efficacy Evaluation: It is frequently used to calculate a "total effective rate" based on the reduction in syndrome scores after treatment. Scoring: Symptoms are typically graded on a scale (e.g., 0 for normal, 2 for mild, 4 for moderate, 6 for severe), and the total score reflects the overall severity of the syndrome |
At 2, 4, 8, and 12 weeks after treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ZDYN-2024-A-147
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .